IKZF1 and acute lymphoblastic leukemia: Deletions or mutations affecting the B-cell transcription factor IKZF1, which occur in 10-15% of pediatric B-cell progenitor ALL (BCP-ALL), were shown to negatively affect cellular responses to a number of therapeutic drugs, thereby increasing the chance of therapy failure (4, 5).